Brandon Allgood

Brandon Allgood is a serial entrepreneur focused on applying ML and large-scale computational methods to improve human health. Brandon’s former companies, Valo Health (MA, USA), Numerate (CA, USA), and Pharmix (CA, USA) are and were groundbreaking companies at the forefront of applying modern ML and computational methods to drug discovery and development in diverse subfields, including chemistry, biology, clinical trials and real-world health data.  Brandon was formerly the Chief AI Officer at Valo Health where he provided technology vision through three venture capital rounds of financing and managed the engineering and data science teams that were developing and applying Valo’s AI-based platform: the Opal Computational Platform.

Prior to Valo Health, Brandon was the co-founder and Chief Technology Officer of Numerate, a leader in ML-driven computational small molecule drug design. At Numerate, he led the engineering and data science teams in developing Numerate’s Data Driven Drug Design (D4) Platform, which was used successfully on more than 30 drug design programs at Numerate and in partnership with small biotechnology and large pharmaceutical companies. Brandon received a B.S. in Physics from the University of Washington (WA, USA), and a Ph.D. in Theoretical Cosmology from the University of California (CA, USA). Brandon has authored scientific publications in astrophysics, solid-state physics and computational biology and chemistry, and has 18 years of experience in large-scale cloud and distributed computing, AI and mathematical modeling. He is also founder and former executive chair of the Alliance for AI in Healthcare (AAIH) (MD,USA), former UCSC Foundation Trustee (CA, USA) and current Baskin School of Engineering (CA, USA) Dean’s Council member.